Compare · JUNS vs LLY
JUNS vs LLY
Side-by-side comparison of Jupiter Neurosciences Inc. (JUNS) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both JUNS and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.09T, about 126445.5x JUNS ($8.6M).
- Over the past year, JUNS is down 94.0% and LLY is up 49.6% - LLY leads by 143.6 points.
- JUNS has been more active in the news (15 items in the past 4 weeks vs 8 for LLY).
- LLY has more recent analyst coverage (25 ratings vs 0 for JUNS).
- Company
- Jupiter Neurosciences Inc.
- Eli Lilly and Company
- Price
- $0.18-2.84%
- $1154.26-2.51%
- Market cap
- $8.6M
- $1.09T
- 1M return
- -20.35%
- -0.54%
- 1Y return
- -94.02%
- +49.58%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2024
- News (4w)
- 15
- 8
- Recent ratings
- 0
- 25
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest JUNS
- Chief Administrative Officer Rosen Alexander Gustaf Erik converted options into 261,161 shares, increasing direct ownership by 73% to 617,411 units (SEC Form 4)
- Director Kampf Julie B. converted options into 82,875 shares (SEC Form 4)
- Director Weis Holger converted options into 85,800 shares, increasing direct ownership by 796% to 96,581 units (SEC Form 4)
- Director Hemmerly Nicholas H. converted options into 95,550 shares (SEC Form 4)
- Chief Scientific Officer Hayward Marshall A. converted options into 1,014,195 shares, increasing direct ownership by 51% to 2,995,077 units (SEC Form 4)
- SEC Form EFFECT filed by Jupiter Neurosciences Inc.
- Jupiter Neurosciences Strengthens Board with Appointment of Dr. Tomas J. Philipson
- SEC Form 4 filed by Director Philipson Tomas Jan
- SEC Form 3 filed by new insider Philipson Tomas Jan
- SEC Form 424B3 filed by Jupiter Neurosciences Inc.
Latest LLY
- A Nasdaq-Listed Regenerative Tissue Company Just Opened a Lab: The Next Step in Scaling a Platform Built for a NEW Aesthetics Opportunity
- Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China
- Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy
- What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management
- Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
- SEC Form 11-K filed by Eli Lilly and Company
- Lilly declares third-quarter 2026 dividend
- International Regulatory Pathways Have Supported Drug Development Across Biotech and Pharma
- Director Sulzberger Gabrielle was granted 4 shares, increasing direct ownership by 0.15% to 2,995 units (SEC Form 4)
- Director Luciano Juan R was granted 14 shares, increasing direct ownership by 0.08% to 16,891 units (SEC Form 4)